

<b>Contacts:</b>			
<b>Biosite Incorporated</b>		<b>Oxford Genome Sciences</b>	
Nadine Padilla	Nicole Beckstrand	Christian Rohlff	David Dible, Valerie Auffray
VP, Corporate & Investor Relations Biosite Incorporated	Manager, Public Relations Biosite Incorporated	Chief Executive Officer Oxford Genome Sciences (UK) Ltd	Citigate Dewe Rogerson
(858) 805-2820	(858) 805-2803	+44 (0) 1235 861770	+44 (0)207 638 9571
<a href="mailto:npadilla@biosite.com">npadilla@biosite.com</a>	nbeckstrand@biosite.com	christian.rohlff@oxfordgenomesciences.com	<a href="mailto:valerie.auffray@citigate.co.uk">valerie.auffray@citigate.co.uk</a>

### **BIOSITE AND OXFORD GENOME SCIENCES ANNOUNCE COLLABORATION IN COLORECTAL CANCER**

**SAN DIEGO and Oxford, UK**—Biosite<sup>®</sup> Incorporated (Nasdaq: BSTE) and privately-held Oxford Genome Sciences (UK) Ltd. (OGeS) today announced a collaboration for the evaluation of protein-based disease markers for colorectal cancer. The markers could be used for the development of potential blood-based diagnostic products aimed at expanding personalized therapeutic options for colorectal cancer. In particular, these blood-based diagnostics would be designed to enable the early identification of colorectal cancer patients that have relapsed, thus enabling clinicians to select the most appropriate therapeutic option.

Today, the fecal occult blood test and colonoscopy, a highly invasive procedure, are the most frequently used screening and diagnostic methods for colorectal cancer, which has a 30 to 40 percent recurrence rate within an average of 18 months after primary diagnosis.<sup>1,2,3,4</sup>

OGeS has developed a database (the Oxford Genome Anatomy Project or OGAP<sup>®</sup>) that integrates genomic, proteomic and clinical information derived from blood and tissue studies for a large number of diseases. Under the terms of the collaboration, OGeS will identify at least 25 proteins discovered in blood and tissue samples from relapsing colorectal cancer patients and Biosite will have the rights to develop blood-based diagnostic tests using one or more of those biomarkers. Financial terms of the agreement were not disclosed.

“We are increasingly interested in studying selected areas of cancer that can benefit from rapid, effective, non-invasive diagnostic technologies,” said Kim Blickenstaff, Biosite’s chairman and chief executive officer. “This collaboration expands our research aimed at evaluation of diagnostic tools for relapsing colorectal cancer by providing us with access to high quality validation of potentially valuable protein biomarkers.”

“Relapsing disease is the major cause of suffering and death in colorectal cancer patients and there is a complete lack of clinical tools to aid physicians in the process of deciding whom to

treat when and whether to treat with chemotherapy,” said Christian Rohlff, OGeS’ chief executive officer. “This collaboration with Biosite underpins our corporate objective of applying new strategies to the emerging field of personalized medicine in oncology to improve patient outcomes.”

More than 1 million Americans have colorectal cancer and more than 140,000 new cases are diagnosed each year. More than 55,000 people died from cancers of the colon/rectum in 2005. Estimated healthcare costs related to treatment for colorectal cancer in the United States are more than \$8 billion.<sup>5</sup> Patients with a primary diagnosis of colorectal cancer are followed up on average every three to six months for the first three years and every six months for the next two years to assess recurrence.<sup>6</sup>

### **About Oxford Genome Sciences**

Oxford Genome Sciences (OGeS) is focused on the development of personalised medicines, mainly for oncology indications. The Company has developed a unique integrated platform that combines genomic, proteomic and clinical information to accelerate the discovery and validation of drug targets and biomarkers in human beings. The benefits are improved biomarkers for patient selection, drug response and efficacy monitoring, and the integration of diagnostics into drug development and product launch, thereby facilitating more accurate drug development and providing cost and time savings.

OGeS’ strategy is to enter into flexible strategic alliances to capture maximum value from its unique and integrated platform for the development of new therapeutics and diagnostics in the field of cancer. In parallel, the Company provides target and biomarker discovery and screening services to pharmaceutical and biotechnology companies providing OGeS with short-term revenues.

OGeS was formed in 2004 and is based near Oxford, UK.

[www.oxfordgenomesciences.com](http://www.oxfordgenomesciences.com)

### **About OGAP<sup>®</sup>**

OGAP holds the world’s largest proprietary collection of proteins represented by the database, which contains over 1 million peptide sequences from 50 tissues and 60 disease states, mapped to approximately 15,000 genes and over 8 million single nucleotide polymorphism and haplotypes. The database can be customised for individual partners to support and enhance their preclinical and clinical drug development activities.

### **About Biosite Incorporated**

Biosite Incorporated is a leading bio-medical company commercializing proteomics discoveries for the advancement of medical diagnosis. The Company’s products contribute to improvements in medical care by aiding physicians in the diagnosis of critical diseases and health conditions. Biosite’s Triage<sup>®</sup> rapid diagnostics are used in approximately 50 percent of U.S. hospitals and in more than 50 international markets. Information on Biosite can be found at [www.biosite.com](http://www.biosite.com).

*Except for the historical information presented herein, matters discussed in this press release are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including but not limited to statements that are preceded by, followed by, or that include the words “will”; “believes”; “should”; “intends”; “anticipates”; “plans”; “expects”; “estimates”; or similar statements are forward-looking statements. Forward looking statements include statements about the potential benefits of the*

## BIOSITE AND OGeS ANNOUNCED COLLABORATION

-3-3-3-

*collaboration to Biosite and Oxford Genome Sciences and Biosite's ability evaluate the diagnostic utility of the biomarker targets. In addition, there can be no guarantees that Biosite will develop any diagnostic product in the field of colorectal cancer or any other form of cancer. Even if Biosite believes it has initially developed such a product, Biosite may not be able to complete the development or obtain the regulatory approvals to commercialize the product. Risks that should be considered include risks and uncertainties regarding the discovery and product development process generally, risks associated with the introduction of competitive products from companies with greater capital and resources, uicteintieua5.2(d pu)5.8.8uc )pacab-(e)8r8p)-1.1(a2.6over)8re8a-1.1((d)5.2( Tw[grm]#1.2(c)6t)5.8h)-1.2()*